Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 259

1.

Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research.

Hampel H, Mesulam MM, Cuello AC, Khachaturian AS, Vergallo A, Farlow MR, Snyder PJ, Giacobini E, Khachaturian ZS.

J Prev Alzheimers Dis. 2019;6(1):2-15. doi: 10.14283/jpad.2018.43.

PMID:
30569080
2.

Sex differences in Alzheimer disease - the gateway to precision medicine.

Ferretti MT, Iulita MF, Cavedo E, Chiesa PA, Schumacher Dimech A, Santuccione Chadha A, Baracchi F, Girouard H, Misoch S, Giacobini E, Depypere H, Hampel H; Women’s Brain Project and the Alzheimer Precision Medicine Initiative.

Nat Rev Neurol. 2018 Aug;14(8):457-469. doi: 10.1038/s41582-018-0032-9. Review.

PMID:
29985474
3.

Sex and Gender Differences in the Brain Cholinergic System and in the Response to Therapy of Alzheimer Disease with Cholinesterase Inhibitors.

Giacobini E, Pepeu G.

Curr Alzheimer Res. 2018;15(11):1077-1084. doi: 10.2174/1567205015666180613111504. Review.

PMID:
29895246
4.

The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.

Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, Khachaturian AS, Vergallo A, Cavedo E, Snyder PJ, Khachaturian ZS.

Brain. 2018 Jul 1;141(7):1917-1933. doi: 10.1093/brain/awy132. Review.

5.

WITHDRAWN: Revisiting the cholinergic hypothesis in Alzheimer's disease: Emerging evidence from translational and clinical research.

Hampel H, Mesulam MM, Cuello AC, Khachaturian AS, Farlow MR, Snyder PJ, Giacobini E, Khachaturian ZS; Cholinergic System Working Group.

Alzheimers Dement. 2017 Oct 10. pii: S1552-5260(17)33719-6. doi: 10.1016/j.jalz.2017.08.016. [Epub ahead of print]

PMID:
29028480
6.

Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.

Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, Démonet JF, Garibotto V, Giannakopoulos P, Gietl A, Hansson O, Herholz K, Jack CR Jr, Nobili F, Nordberg A, Snyder HM, Ten Kate M, Varrone A, Albanese E, Becker S, Bossuyt P, Carrillo MC, Cerami C, Dubois B, Gallo V, Giacobini E, Gold G, Hurst S, Lönneborg A, Lovblad KO, Mattsson N, Molinuevo JL, Monsch AU, Mosimann U, Padovani A, Picco A, Porteri C, Ratib O, Saint-Aubert L, Scerri C, Scheltens P, Schott JM, Sonni I, Teipel S, Vineis P, Visser PJ, Yasui Y, Winblad B.

Lancet Neurol. 2017 Aug;16(8):661-676. doi: 10.1016/S1474-4422(17)30159-X. Epub 2017 Jul 11. Review.

PMID:
28721928
7.

The biomarker-based diagnosis of Alzheimer's disease. 1-ethical and societal issues.

Porteri C, Albanese E, Scerri C, Carrillo MC, Snyder HM, Martensson B, Baker M, Giacobini E, Boccardi M, Winblad B, Frisoni GB, Hurst S; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:132-140. doi: 10.1016/j.neurobiolaging.2016.07.011. Review.

PMID:
28317644
8.

A Study of Aβ Oligomers in the Temporal Cortex and Cerebellum of Patients with Neuropathologically Confirmed Alzheimer's Disease Compared to Aged Controls.

Savioz A, Giannakopoulos P, Herrmann FR, Klein WL, Kövari E, Bouras C, Giacobini E.

Neurodegener Dis. 2016;16(5-6):398-406. doi: 10.1159/000446283. Epub 2016 Jul 12.

PMID:
27400224
9.

Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future.

Hampel H, Schneider LS, Giacobini E, Kivipelto M, Sindi S, Dubois B, Broich K, Nisticò R, Aisen PS, Lista S.

Expert Rev Neurother. 2015 Jan;15(1):83-105. doi: 10.1586/14737175.2015.995637. Epub 2014 Dec 24. Review.

PMID:
25537424
10.

Individual severity of AD-type lesions, Aß oligomers, and comorbidity in the brain aging.

Bouras C, Kovari E, Savioz A, Giacobini E, Xekardaki A.

Adv Exp Med Biol. 2015;822:17. doi: 10.1007/978-3-319-08927-0_4. No abstract available.

PMID:
25416972
11.

Neuropathological changes in aging brain.

Xekardaki A, Kövari E, Gold G, Papadimitropoulou A, Giacobini E, Herrmann F, Giannakopoulos P, Bouras C.

Adv Exp Med Biol. 2015;821:11-7. doi: 10.1007/978-3-319-08939-3_6. Review.

PMID:
25416106
12.

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014.

Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad B, Kivipelto M.

J Intern Med. 2014 Mar;275(3):251-83. doi: 10.1111/joim.12191. Review.

13.

A new roadmap for drug development for Alzheimer's disease.

Becker RE, Greig NH, Giacobini E, Schneider LS, Ferrucci L.

Nat Rev Drug Discov. 2014 Feb;13(2):156. doi: 10.1038/nrd3842-c2. Epub 2013 Dec 20. No abstract available.

14.

Alzheimer disease therapy--moving from amyloid-β to tau.

Giacobini E, Gold G.

Nat Rev Neurol. 2013 Dec;9(12):677-86. doi: 10.1038/nrneurol.2013.223. Epub 2013 Nov 12. Review.

PMID:
24217510
15.

Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.

Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, Sperling R, Wilcock GK, Fox N, Scheltens P, Touchon J, Hendrix S, Andrieu S, Aisen P; EU/US/CTAD Task Force Members.

Alzheimers Dement. 2013 Jul;9(4):438-44. doi: 10.1016/j.jalz.2013.03.007.

PMID:
23809364
16.

Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study.

Simioni S, Cavassini M, Annoni JM, Métral M, Iglesias K, Rimbault Abraham A, Jilek S, Calmy A, Müller H, Fayet-Mello A, Giacobini E, Hirschel B, Du Pasquier RA.

Neurology. 2013 Feb 5;80(6):553-60. doi: 10.1212/WNL.0b013e3182815497. Epub 2013 Jan 23.

PMID:
23345635
17.

Phenserine efficacy in Alzheimer's disease.

Winblad B, Giacobini E, Frölich L, Friedhoff LT, Bruinsma G, Becker RE, Greig NH.

J Alzheimers Dis. 2010;22(4):1201-8. doi: 10.3233/JAD-2010-101311.

18.

Cognitive dysfunction in HIV patients despite long-standing suppression of viremia.

Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, Calmy A, Chave JP, Giacobini E, Hirschel B, Du Pasquier RA.

AIDS. 2010 Jun 1;24(9):1243-50. doi: 10.1097/QAD.0b013e3283354a7b.

PMID:
19996937
19.

[New spectrum of HIV-associated cognitive disorders in the HAART era].

Du Pasquier R, Cavassini M, Simioni S, Annoni JM, Giacobini E, Hirschel B.

Rev Med Suisse. 2009 Apr 29;5(201):955-6, 958-61. French.

PMID:
19476058
20.

Advances in Alzheimer therapy: understanding pharmacological approaches to the disease.

Martínez A, Lahiri DK, Giacobini E, Greig NH.

Curr Alzheimer Res. 2009 Apr;6(2):83-5.

21.

Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?

Becker RE, Greig NH, Giacobini E.

J Alzheimers Dis. 2008 Oct;15(2):303-25. Review.

22.

Advances in Alzheimer therapy: development of innovative new strategies.

Greig NH, Giacobini E, Lahiri DK.

Curr Alzheimer Res. 2007 Sep;4(4):336-9. No abstract available.

PMID:
17908034
23.

One hundred years after the discovery of Alzheimer's disease. A turning point for therapy?

Giacobini E, Becker RE.

J Alzheimers Dis. 2007 Aug;12(1):37-52. Review.

PMID:
17851193
24.

Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer's disease: randomised controlled trial.

Onder G, Zanetti O, Giacobini E, Frisoni GB, Bartorelli L, Carbone G, Lambertucci P, Silveri MC, Bernabei R.

Br J Psychiatry. 2005 Nov;187:450-5.

PMID:
16260821
25.

Editorial: advances in Alzheimer therapy: something old, something new, something borrowed, something blue.

Greig NH, Lahiri DK, Giacobini E.

Curr Alzheimer Res. 2005 Jul;2(3):275-9. Review. No abstract available.

PMID:
15974892
26.

[The economical impact of dementia].

Bonin-Guillaume S, Zekry D, Giacobini E, Gold G, Michel JP.

Presse Med. 2005 Jan 15;34(1):35-41. Review. French.

PMID:
15685097
27.

Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment.

Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Bäckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC.

J Intern Med. 2004 Sep;256(3):240-6. Review.

28.

Cholinesterase inhibitors: new roles and therapeutic alternatives.

Giacobini E.

Pharmacol Res. 2004 Oct;50(4):433-40. Review.

PMID:
15304240
29.

Cholinergic function and Alzheimer's disease.

Giacobini E.

Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S1-5. Review.

PMID:
12973744
30.

Cholinesterases: new roles in brain function and in Alzheimer's disease.

Giacobini E.

Neurochem Res. 2003 Apr;28(3-4):515-22. Review.

PMID:
12675140
31.

A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease.

Lahiri DK, Farlow MR, Sambamurti K, Greig NH, Giacobini E, Schneider LS.

Curr Drug Targets. 2003 Feb;4(2):97-112. Review.

PMID:
12558063
32.

Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer' disease.

Giacobini E.

J Neural Transm Suppl. 2002;(62):181-7. Review.

PMID:
12456062
33.
34.
35.

Brain energy metabolism in Alzheimer's disease: 99mTc-HMPAO SPECT imaging during verbal fluency and role of astrocytes in the cellular mechanism of 99mTc-HMPAO retention.

Slosman DO, Ludwig C, Zerarka S, Pellerin L, Chicherio C, de Ribaupierre A, Annoni JM, Bouras C, Herrmann F, Michel JP, Giacobini E, Magistretti PJ.

Brain Res Brain Res Rev. 2001 Oct;36(2-3):230-40.

PMID:
11690620
36.

Treatment of Alzheimer's disease. New developments.

Giacobini E, Michel JP.

Ann Med Interne (Paris). 1998 Jun;149(4):231-7.

PMID:
11490551
37.
38.

Economic considerations of Alzheimer's disease and related disorders.

Michel JP, Zekry D, Mulligan R, Giacobini E, Gold G.

Aging (Milano). 2001 Jun;13(3):255-60. Review.

PMID:
11442307
39.

Is anti-cholinesterase therapy of Alzheimer's disease delaying progression?

Giacobini E.

Aging (Milano). 2001 Jun;13(3):247-54. Review.

PMID:
11442306
40.

Cholinesterase inhibitors stabilize Alzheimer's disease.

Giacobini E.

Ann N Y Acad Sci. 2000;920:321-7. Review.

PMID:
11193171
41.

Cholinesterase inhibitors stabilize Alzheimer disease.

Giacobini E.

Neurochem Res. 2000 Oct;25(9-10):1185-90. Review.

PMID:
11059792
42.

Present and future of Alzheimer therapy.

Giacobini E.

J Neural Transm Suppl. 2000;59:231-42. Review.

PMID:
10961434
43.

Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer disease.

Giacobini E.

Alzheimer Dis Assoc Disord. 2000;14 Suppl 1:S3-10. Review.

PMID:
10850724
44.

Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein.

Wevers A, Monteggia L, Nowacki S, Bloch W, Schütz U, Lindstrom J, Pereira EF, Eisenberg H, Giacobini E, de Vos RA, Steur EN, Maelicke A, Albuquerque EX, Schröder H.

Eur J Neurosci. 1999 Jul;11(7):2551-65.

PMID:
10383644
45.

Aging, Alzheimer's disease, and estrogen therapy.

Giacobini E.

Exp Gerontol. 1998 Nov-Dec;33(7-8):865-9. Review.

PMID:
9951629
46.

Cholinergic foundations of Alzheimer's disease therapy.

Giacobini E.

J Physiol Paris. 1998 Jun-Aug;92(3-4):283-7. Review.

PMID:
9789824
47.
48.

Metrifonate. A viewpoint.

Giacobini E.

Drugs Aging. 1997 Dec;11(6):497. Review. No abstract available.

PMID:
9413707
49.

From molecular structure to Alzheimer therapy.

Giacobini E.

Jpn J Pharmacol. 1997 Jul;74(3):225-41. Review.

50.

Nicotinic agonist modulation of neurotransmitter levels in the rat frontoparietal cortex.

Summers KL, Kem WR, Giacobini E.

Jpn J Pharmacol. 1997 Jun;74(2):139-46.

Supplemental Content

Loading ...
Support Center